Deep Dives, AI, Drug Development, Drug Discovery.
based on scans of tumor biopsy samples. That program, dubbed MesoNet, which was detailed in a 2019 publication in Nature, could also visually highlight the areas of the tissue slide that drove its predictions to help pathologists better classify patients. And last month Owkin announced that two of